ClinicalTrials.gg
Status unknownNCT05419245FINDFSSUpdated Jul 19, 2022

Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome

An observational study in Freeman-Burian Syndrome, Freeman-Sheldon Syndrome and Whistling Face Syndrome, sponsored by Dufresne, Craig, MD, PC. Status unknown at 1 site in United States. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Dufresne, Craig, MD, PC · Observational

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
20
Sex
All
01

Study summary

The purpose of this study is to evaluate the difference in diagnosis accuracy, treatment outcomes, patient perspectives, facial function and walking ability, emotional and social health, and respiratory complications between Freeman-Burian syndrome (formerly, Freeman-Sheldon or whistling face syndrome), Sheldon-Hall syndrome, and distal arthrogryposis types 3, and 1.

The approximate cumulative total time for study-related activities will be 3 hours, including email communication, survey completion, and a medical interview.

The study will involve completing 6 short ½ to 1-page surveys and participating in a medical interview. Participants may be asked to provide medical records for review. All study-related activities will take place remotely, and no travel is required.

Read the detailed description

According to the only study of patients and a recent study of individual case reports, Freeman-Burian syndrome (FBS) may be over-diagnosed by 33-66%, and it is most often confused with Sheldon-Hall syndrome and distal arthrogryposis (DA) types 3 and 1. Unfortunately, while these conditions are different from FBS, many think of them as being less severe versions of FBS. This is not true. FBS is a skull and face syndrome, while Sheldon-Hall syndrome and DA types 1 and 3 are syndromes of the arms, legs, hands, and feet that (except DA type 1) may have mild face deformities. It is important to understand this difference, FBS does not respond well to treatment. The other syndromes generally do respond well to treatment. To improve diagnosis and treatment, it is important to understand factors contributing to an accurate diagnosis and treatment outcome. To provide better evidence for these being very different syndromes, it also is important to compare the above areas of health between people with all of these syndromes. It is hoped the study will help improve treatment and identify areas for further research.

02

Conditions studied

  • Freeman-Burian Syndrome
  • Freeman-Sheldon Syndrome
  • Whistling Face Syndrome
  • Sheldon-Hall Syndrome
  • Freeman-Sheldon Syndrome Variant
  • Arthrogryposis Distal Type 1
  • Arthrogryposis Distal Type 3
  • Gordon Syndrome

Keywords

  • craniofacial abnormalities
  • arthrogryposis
  • rehabilitation
  • surgery
  • therapy
  • health status
  • quality of life
  • patient reported outcome
  • health-related quality of life
  • depressive symptoms
03

In context

Craniofacial Abnormalities

22 studies on the registry are indexed under Craniofacial Abnormalities; 3 are open to participants now.

This study's planned enrollment of 20 is below the median of 77 across 12 observational studies indexed under Craniofacial Abnormalities.

Browse Craniofacial Abnormalities studies →

Lead sponsor

Dufresne, Craig, MD, PC is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

There are no patient enrollment restrictions based on gender, ethnicity, religion, socio-economic status, geographical location, or clinical setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are able to provide or have a legally appointed representative who is able to provide informed consent
  • Patients who have Freeman-Burian syndrome (formerly, Freeman-Sheldon syndrome), Sheldon-Hall syndrome, distal arthrogryposis type 1, or distal arthrogryposis type 3
  • Persons who speak and read English, German, Russian, or Czech

Exclusion criteria

Exclusion Criteria:

  • Patients who are not able to provide or do not have a legally appointed representative who is able to provide informed consent
  • Patients who do not have Freeman-Burian syndrome (formerly, Freeman-Sheldon syndrome), Sheldon-Hall syndrome, distal arthrogryposis type 1, or distal arthrogryposis type 3
  • Persons who do not speak or read English, German, Russian, or Czech
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Freeman-Sheldon syndrome Classic Type

    Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); "H" or "V" shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.

    Other: Guided Health History for Freeman-Burian Syndrome Questionnaire · Other: Freeman-Burian syndrome Semi-Structured Quality of Life Interview · Other: Medical Records Review · Other: PTSD Checklist for DSM-5 · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale · Other: Review of Systems · Other: FACE-Q | Craniofacial - Appearance of the Face · Other: FACE-Q | Craniofacial - Appearance Distress · Other: FACE-Q | Craniofacial - Facial Function

  • Freeman-Sheldon syndrome Craniofacial Type

    Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), "H" or "V" shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases).

    Other: Guided Health History for Freeman-Burian Syndrome Questionnaire · Other: Freeman-Burian syndrome Semi-Structured Quality of Life Interview · Other: Medical Records Review · Other: PTSD Checklist for DSM-5 · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale · Other: Review of Systems · Other: FACE-Q | Craniofacial - Appearance of the Face · Other: FACE-Q | Craniofacial - Appearance Distress · Other: FACE-Q | Craniofacial - Facial Function

  • Freeman-Sheldon syndrome Mixed Type

    Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.

    Other: Guided Health History for Freeman-Burian Syndrome Questionnaire · Other: Freeman-Burian syndrome Semi-Structured Quality of Life Interview · Other: Medical Records Review · Other: PTSD Checklist for DSM-5 · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale · Other: Review of Systems · Other: FACE-Q | Craniofacial - Appearance of the Face · Other: FACE-Q | Craniofacial - Appearance Distress · Other: FACE-Q | Craniofacial - Facial Function

  • Sheldon-Hall syndrome

    Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.

    Other: Guided Health History for Freeman-Burian Syndrome Questionnaire · Other: Freeman-Burian syndrome Semi-Structured Quality of Life Interview · Other: Medical Records Review · Other: PTSD Checklist for DSM-5 · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale · Other: Review of Systems · Other: FACE-Q | Craniofacial - Appearance of the Face · Other: FACE-Q | Craniofacial - Appearance Distress · Other: FACE-Q | Craniofacial - Facial Function

  • Distal Arthrogryposis Type 1

    Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.

    Other: Medical Records Review · Other: PTSD Checklist for DSM-5 · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale · Other: Review of Systems

  • Distal Arthrogryposis Type 3

    Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and spine curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.

    Other: Medical Records Review · Other: PTSD Checklist for DSM-5 · Other: Modified Flanagan Quality of Life Scale · Other: Center for Epidemiologic Studies Depression Scale · Other: Review of Systems · Other: FACE-Q | Craniofacial - Appearance of the Face · Other: FACE-Q | Craniofacial - Appearance Distress · Other: FACE-Q | Craniofacial - Facial Function

Interventions

  • OtherGuided Health History for Freeman-Burian Syndrome Questionnaire

    Completed during the interview. The Guided Health History for Freeman-Burian Syndrome Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.

  • OtherFreeman-Burian syndrome Semi-Structured Quality of Life Interview

    Completed during the interview. Freeman-Burian syndrome Semi-Structured Quality of Life Interview is a quality of life interview for Freeman-Burian syndrome, taking into consideration individual's total health.

  • OtherMedical Records Review

    Review of medical records will be used, along with Guided Health History for Freeman-Burian Syndrome Questionnaire to assess patient histories and outcomes.

    Also known as: treatment records review, review of patient notes, patient chart review, review of clinical data

  • OtherPTSD Checklist for DSM-5

    Completed by patients before the interview. The PTSD Checklist for DSM-5 is a 20-item questionnaire. Each item is rated 0-4, with 0 being "Not at all" and 4 being "Extremely". Lower scores suggest the person may be experiencing fewer symptoms.

  • OtherModified Flanagan Quality of Life Scale

    Completed by patients before the interview. The Modified Flanagan Quality of Life Scale is a 16-item survey designed for use in persons with chronic illness. Each item is rated 1-7, with 1 being "Terrible" and 7 being "Delighted". Higher scores suggest the person may be experiencing a better quality of life.

  • OtherCenter for Epidemiologic Studies Depression Scale

    Completed by patients before the interview. The Center for Epidemiologic Studies Depression Scale is a 20-item survey that asks about depressive feelings and behaviours in the past week. Each item is rated 0-3, with 0 being "Rarely or none of the time (less than 1 day)" and 3 being "Most or all of the time (5-7 days)". Lower scores suggest the person may be experiencing fewer symptoms.

  • OtherReview of Systems

    Completed during the interview. A review of systems is a checklist of medical problems.

    Also known as: health history, medical history

  • OtherFACE-Q | Craniofacial - Appearance of the Face

    Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being "Not at All" and 4 being "Very Much". Lower scores suggest the person may be less pleased with the appearance of their face.

  • OtherFACE-Q | Craniofacial - Appearance Distress

    Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being "Always" and 4 being "Never". Lower scores suggest the person may be experiencing more distress related to the appearance of their face.

  • OtherFACE-Q | Craniofacial - Facial Function

    Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being "I cannot do this" and 3 being "I can do this". Lower scores suggest the person may be experiencing more problems with facial muscle functioning.

06

What researchers measure

Primary outcomes

  1. Difference in intervention-related outcome rates between groups

    Outcomes for all interventions are rated as either acceptable, unacceptable, or potentially harmful/harmful. Information related to outcomes of interventions is collected using the Guided Health History for Freeman-Burian Syndrome Questionnaire, Review of Systems forms, and Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  2. Difference in diagnostic accuracy between groups

    This is the percent of patients with a stated diagnosis re-screened by study investigators with the same diagnosis. Diagnostic information is collected using the Guided Health History for Freeman-Burian Syndrome Questionnaire and Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

Secondary outcomes

  1. Difference in posttraumatic stress disorder symptoms between groups

    Posttraumatic stress symptoms are assessed using the self-completed and validated PTSD Checklist for DSM-5, a 20-item questionnaire; each item is rated 0-4, with 0 being "Not at all" and 4 being "Extremely".

    Time frame: 1 week to 1 day before a single study interview, which lasts 1-2 hours

  2. Difference in depressive symptoms between groups

    Depressive symptoms are assessed using the self-completed and validated Center for Epidemiologic Studies Depression Scale.

    Time frame: 1 week to 1 day before a single study interview, which lasts 1-2 hours

  3. Difference in quality-of-life between groups

    Quality-of-life is scored using the self-completed Modified Flanagan Quality of Life Scale.

    Time frame: 1 week to 1 day before a single study interview, which lasts 1-2 hours

  4. Difference in facial appearance satisfaction between groups

    Facial appearance satisfaction is scored using the self-completed FACE-Q \| Craniofacial - Appearance of the Face.

    Time frame: 1 week to 1 day before a single study interview, which lasts 1-2 hours

  5. Difference in facial appearance distress between groups

    Facial appearance distress is scored using the self-completed FACE-Q \| Craniofacial - Appearance Distress.

    Time frame: 1 week to 1 day before a single study interview, which lasts 1-2 hours

  6. Difference in facial muscle functioning symptoms between groups

    Facial muscle functioning symptoms are scored using the self-completed FACE-Q \| Craniofacial - Facial Function.

    Time frame: 1 week to 1 day before a single study interview, which lasts 1-2 hours

Other outcomes

  1. Difference in diagnostic accuracy between specialities between all sub-types of Freeman-Burian syndrome and the other diagnosis groups (Sheldon-Hall syndrome, distal arthrogryposis type 3, and distal arthrogryposis type 1)

    Diagnostic accuracy is the percent of patients with a stated diagnosis re-screened by study investigators with the same diagnosis. Specialities include: orthopedics, plastic surgery, anesthesia, pediatrics, and medical genetics. Diagnostic information is collected using the Guided Health History for Freeman-Burian Syndrome Questionnaire and Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  2. Difference in head and face (craniofacial) surgery-related outcome rates between groups

    Outcomes for all head and face (craniofacial) surgeries are rated as either acceptable, unacceptable, or harmful/potentially harmful. Information related to outcomes of interventions is collected using the Guided Health History for Freeman-Burian Syndrome Questionnaire, Review of Systems forms, and Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  3. Difference in spine surgery-related outcome rates between groups

    Outcomes for all spine surgeries are rated as either acceptable, unacceptable, or harmful/potentially harmful. Information related to outcomes of interventions is collected using the Guided Health History for Freeman-Burian Syndrome Questionnaire, Review of Systems forms, and Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  4. Difference in foot and ankle surgery-related outcome rates between groups

    Outcomes for all foot and ankle surgeries are rated as either acceptable, unacceptable, or harmful/potentially harmful. Information related to outcomes of interventions is collected using the Guided Health History for Freeman-Burian Syndrome Questionnaire, Review of Systems forms, and Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  5. Difference in hand and wrist surgery-related outcome rates between groups

    Outcomes for all hand and wrist surgeries are rated as either acceptable, unacceptable, or harmful/potentially harmful. Information related to outcomes of interventions is collected using the Guided Health History for Freeman-Burian Syndrome Questionnaire, Review of Systems forms, and Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  6. Difference in other bone and joint surgery-related outcome rates between groups

    Outcomes for other bone and joint surgeries are rated as either acceptable, unacceptable, or harmful/potentially harmful. Information related to outcomes of interventions is collected using the Guided Health History for Freeman-Burian Syndrome Questionnaire, Review of Systems forms, and Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  7. Difference in general anesthesia-related complication rates between groups

    The course of general anesthesia-related is rated as either routine, minor, complication, major complication, or failure. Information related to complications of interventions is collected using the Guided Health History for Freeman-Burian Syndrome Questionnaire, Review of Systems forms, and Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  8. Difference in respiratory-related complication rates between groups

    Respiratory-related complications are assessed using the Guided Health History for Freeman-Burian Syndrome Questionnaire. Additional information on physical findings is collected using the Review of Systems forms and from the Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  9. Difference in rates of difficulty eating (chewing and swallowing) between groups

    Difficulty eating (chewing and swallowing) is assessed using the Guided Health History for Freeman-Burian Syndrome Questionnaire. Additional information on physical findings is collected using the Review of Systems forms and from the Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  10. Difference in rates of difficulty walking between groups

    Difficulty walking is assessed using the Guided Health History for Freeman-Burian Syndrome Questionnaire. Additional information on physical findings is collected using the Review of Systems forms and from the Medical Records Review.

    Time frame: During a single study interview, which lasts 1-2 hours

  11. Qualitative difference in quality of life between groups

    Qualitative assessment is done using the Freeman-Burian syndrome Semi-Structured Quality of Life Interview, a guided interview consisting of open-ended questions.

    Time frame: During a single study interview, which lasts 1-2 hours

07

Study locations

1 of 1 sites recruiting
  • Office of Craig R Dufresne, MD, PC
    Fairfax, Virginia 22031, United States
    Recruiting
    • Craig R Dufresne, MD · Contactinfo@duplastics.com · 703-207-3065
    • Mikaela I Poling, BA · Contactresearch@duplastics.com · 703-207-3065
    • Craig R Dufresne, MD · Principal investigator
    • Mikaela I Poling, BA · Sub investigator
08

References and documents

Publications

  • Poling MI, Dufresne CR, Chamberlain RL. Dr Ben Franklin and an unusual modern-day cure for recurrent pleuritis. Br J Gen Pract. 2017 Jan;67(654):32-33. doi: 10.3399/bjgp17X688705. No abstract available. PubMed 28034943 ↗
  • Poling MI, Dufresne CR. Head First, Not Feet First: Freeman-Sheldon Syndrome as Primarily a Craniofacial Condition. Cleft Palate Craniofac J. 2018 May;55(5):787-788. doi: 10.1177/1055665617753482. Epub 2018 Jan 25. PubMed 29370530 ↗
  • Poling MI, Dufresne CR. Revisiting the Many Names of Freeman-Sheldon Syndrome. J Craniofac Surg. 2018 Nov;29(8):2176-2178. doi: 10.1097/SCS.0000000000004802. PubMed 30400128 ↗
  • Poling MI, Dufresne CR, Chamberlain RL. Freeman-Burian syndrome. Orphanet J Rare Dis. 2019 Jan 10;14(1):14. doi: 10.1186/s13023-018-0984-2. PubMed 30630514 ↗
  • Poling MI, Dufresne CR. Epidemiology, prevention, diagnosis, treatment, and outcomes for psychosocial problems in patients and families affected by non-intellectually impairing craniofacial malformation conditions: a systematic review protocol of qualitative data. Syst Rev. 2019 May 27;8(1):127. doi: 10.1186/s13643-019-1045-1. PubMed 31133050 ↗
  • Poling MI, Dufresne CR. Freeman-Burian syndrome. Anasthesiologie und Intensivmedizin. 2019; 60(1): S8-S17. doi: 10.19224/ai2019.S008
  • Poling MI, Dufresne CR, Portillo AL. Identification and Recent Approaches for Evaluation, Operative Counseling, and Management in Patients With Freeman-Burian Syndrome: Principles for Global Treatment. J Craniofac Surg. 2019 Nov-Dec;30(8):2502-2508. doi: 10.1097/SCS.0000000000005968. PubMed 31567769 ↗
  • Poling MI, Dufresne CR. Distal arthrogryposis type 3. Anasthesiologie und Intensivmedizin. 2019; 60(13): S536-S543. doi: 10.19224/ai2019.s536.
  • Poling MI, Dufresne CR. Identification and Recent Approaches for Evaluation and Management of Dentofacial and Otolaryngologic Concerns for Patients With Freeman-Burian Syndrome: Principles for Global Treatment. J Craniofac Surg. 2020 May/Jun;31(3):787-790. doi: 10.1097/SCS.0000000000006155. PubMed 31985597 ↗
  • Poling MI, Dufresne CR, Chamberlain RL. Findings, Phenotypes, Diagnostic Accuracy, and Treatment in Freeman-Burian Syndrome. J Craniofac Surg. 2020 Jun;31(4):1063-1069. doi: 10.1097/SCS.0000000000006299. PubMed 32149971 ↗
  • Poling MI, Dufresne CR, McCormick RJ. Identification and Recent Approaches for Evaluation and Management of Rehabilitation Concerns for Patients with Freeman-Burian Syndrome: Principles for Global Treatment. J Pediatr Genet. 2020 Sep;9(3):158-163. doi: 10.1055/s-0040-1710339. Epub 2020 May 7. PubMed 32714615 ↗
  • Poling MI, Dufresne CR. Letter. AANA Journal. 2020; 88(5): 54.
  • Poling MI, Dufresne CR. Letter: Precise Pulmonary Function Evaluation and Management of a Patient With Freeman-Sheldon Syndrome Associated With Recurrent Pneumonia and Chronic Respiratory Insufficiency (Ann Rehabil Med 2020;44:165-70). Ann Rehabil Med. 2020 Oct;44(5):409-410. doi: 10.5535/arm.20110. Epub 2020 Oct 29. No abstract available. PubMed 33152847 ↗
  • Poling MI, Dufresne CR. Accuracy of facts about Freeman-Sheldon syndrome. Clinical and Experimental Obstetrics and Gynecolology. 2021; 48(5): 997-998. doi: 10.31083/j.ceog4805160
  • Poling MI, Dufresne CR. Diagnosis, evaluation, and treatment in Freeman-Burian syndrome: clinical practice guideline for a rare and complex craniofacial syndrome. Craniomaxillofacial Abstracts Presented at 78th Annual Meeting of the American Cleft Palate Craniofacial Meeting. FACE. 2021; 2(4): NP3. doi: 10.1177/27325016211049488
  • Poling MI, Dufresne CR. Clarity on Diagnosis in Freeman-Burian syndrome. Turkiye Klinikleri Journal of Case Reports. doi: 10.5336/caserep.2022-88270 [In Press] Available online: 17 February 2022. Available at: https://www.turkiyeklinikleri.com/inpress_article/en-clarity-on-diagnosis-in-freeman-burian-syndrome-97915.html
  • Poling MI, Dufresne CR. Oculoplastic surgery, diagnosis, and other matters in Freeman-Burian syndrome. Ophthalmic Genet. 2022 Jun;43(3):431-432. doi: 10.1080/13816810.2022.2068043. Epub 2022 Apr 28. No abstract available. PubMed 35484845 ↗
  • Poling MI, Dufresne CR. Anaesthesia recommendations for Sheldon-Hall syndrome. OrphanAnesthesia. 20 Feb 2019. Available at: https://www.orphananesthesia.eu/en/rare-diseases/published-guidelines/cat_view/61-rare-diseases/60-published-guidelines/237-sheldon-hall-syndrome.html
  • Poling MI, Dufresne CR. Obstetrics and Diagnosis in Freeman-Burian syndrome. Version: 1. Authorea [preprint]. January 31, 2022. doi: 10.22541/au.164366820.09260728/v1.
  • Poling MI, Dufresne CR. Misinformation and Misdiagnosis in Freeman-Burian syndrome. Version: 1. Authorea [preprint]. January 31, 2022. doi: 10.22541/au.164366815.52860865/v1.
  • Poling MI, Dufresne CR. Limb Deformity Treatment and Diagnosis in Freeman-Burian syndrome. Version: 1. Authorea [preprint]. January 31, 2022. doi: 10.22541/au.164366820.05370920/v1.
  • Poling MI, Dufresne CR. Unsafe Care and Misunderstanding Diagnosis in Freeman-Burian syndrome: Problems in Writing Case Reports Involving Rare Conditions and Strategies for Improvement. Authorea. January 24, 2022. doi: 10.22541/au.164303994.43963430/v1.
  • Poling MI, Morales Corado JA, Chamberlain RL. Findings, phenotypes, and outcomes in Freeman-Sheldon and Sheldon-Hall syndromes and distal arthrogryposis types 1 and 3: protocol for systematic review and patient-level data meta-analysis. Syst Rev. 2017 Mar 6;6(1):46. doi: 10.1186/s13643-017-0444-4. PubMed 28264711 ↗
  • Poling MI, Dufresne CR. Re: "Periocular Anomalies in Freeman-Sheldon Syndrome". Ophthalmic Plast Reconstr Surg. 2022 Nov-Dec 01;38(6):609-610. doi: 10.1097/IOP.0000000000002307. Epub 2021 Nov 4. No abstract available. PubMed 36326430 ↗

Individual participant data

Plan to share: No — No individual participant data (IPD) will be made available to other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Dec 2023, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2022
First posted
Jun 15, 2022
StartActual
Jun 1, 2022
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
Jul 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05419245
Lead sponsor
Dufresne, Craig, MD, PC
Responsible party
Sponsor
First posted
Jun 15, 2022
Start date
Jun 1, 2022
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Jul 19, 2022

Study contacts

Mikaela I Poling, BA
Contact
research@duplastics.com
3044609038
Craig R Dufresne, MD
Contact
info@duplastics.com
7032073065
Craig R Dufresne, MD
principal investigator · Dr Craig R Dufresne, MD, PC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion